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ABSTRACT
Amikacin-resistant Escherichia coli strains are iso-
lated rarely from clinical samples. In the present
study, investigation of an amikacin-resistant clin-
ical isolate of E. coli demonstrated the presence of
two class 1 integrons carrying the aacA4 gene plus
the aacA7 gene, and the dfrA17 gene plus the
aadA5 gene, respectively. Resistance to amikacin
in this E. coli isolate was related to the presence of
both aacA4 and aacA7.
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rons, resistance
Original Submission: 26 May 2004; Accepted: 6 July
2004
Clin Microbiol Infect 2005; 11: 71–73
10.1111/j.1469-0691.2004.01039.x
During recent years, a dramatic increase has been
observed in the number of multiresistant micro-
organisms. In Escherichia coli, high levels of resist-
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ance to a great variety of antimicrobial agents have
emerged [1–3], but E. coli rarely exhibits resistance
to some antimicrobial agents, such as amikacin or
imipenem [1,3–8]. However, in 2002, a multire-
sistant isolate of E. coli was recovered from
sputum of a patient with a long history of
bronchial asthma. The patient presented with
persistent purulent bronchial hypersecretion, and
had been treated with bronchodilators, systemic
corticosteroids and nebulised tobramycin for
previous recurrent episodes of respiratory tract
infections caused by Pseudomonas aeruginosa. The
aim of the present study was to analyse the
different mechanisms of antibiotic resistance in
the E. coli isolate, paying particular attention to
the mechanisms of resistance involved in amika-
cin resistance.
Susceptibilities to ampicillin, ceftriaxone, ceft-
azidime, cefepime, cefotaxime, aztreonam, cefaz-
olin, cefoxitin, cefuroxime, ampicillin–sulbactam,
ticarcillin, piperacillin, imipenem, meropenem,
amoxycillin–clavulanic acid, co-trimoxazole,
ciproﬂoxacin, oﬂoxacin, tobramycin, gentamicin
and amikacin were determined with the Micro-
scan system (Dade-Behring, Sacramento, CA,
USA). The E. coli isolate was resistant to all the
antibacterial agents tested, with the exception of
imipenem, meropenem, aztreonam, ceftazidime,
cefoxitin and ceftriaxone; intermediate resistance
was observed to amoxycillin–clavulanic acid.
PCR to detect the presence of type 1 integrons
was performed as described previously [9]. The
ampliﬁed products were sequenced with a Big-
Dye Terminator v. 3.1 Cycle Sequencing Kit
(Perkin Elmer, Emeryville, CA, USA), following
the manufacturer’s instructions, in an ABI 377
automated sequencer (Perkin Elmer). An integron
of c. 1500 bp was detected, containing an aacA4
gene (encoding AAC(6¢)Ib) plus an aacA7gene
(encoding AAC(6¢)Il). However, when the PCR
was repeated to conﬁrm this result, an integron of
a similar size, containing a dfrA17 gene plus an
aadA5 gene, was detected. The presence of these
two different integrons was conﬁrmed by PCR
with speciﬁc primers for the aacA4 [10] and dfrA17
[11] genes.
The presence of b-lactamases was examined by
PCR with primers to amplify TEM-like, SHV-like
and OXA-1-like genes [12]. Only the primers for
OXA-1-like genes ampliﬁed a DNA fragment of
the expected size, which was identiﬁed as enco-
ding an OXA-30 b-lactamase by DNA sequencing.
This b-lactamase has been reported previously in
Spain, in E. coli isolates from the faeces of healthy
individuals [1] and from clinical specimens [13],
and has been associated with decreased suscep-
tibility to amoxycillin–clavulanic acid.
Resistance to amikacin is an unusual observa-
tion in E. coli isolates from Spain and other
countries [1,3,5–8]. Previous studies in Spain with
E. coli isolates of human (children and adults),
animal or food origin have failed to detect
resistance to this antimicrobial agent [3,5]. The
resistance to amikacin, as well as to tobramycin,
observed in the isolate analysed in the present
study may be related to the joint presence of
aacA4 and aacA7, which both encode aminogly-
coside-modifying enzymes capable of inactivating
amikacin. Interestingly, previous use of tobramy-
cin to treat the patient may have been important
in selecting resistance from the patient’s endog-
enous ﬂora, although it is clearly not possible to
exclude an exogenous source for this amikacin-
resistant E. coli strain. The amikacin resistance-
encoding genes detected in this study have been
described previously in various Enterobacteria-
ceae, including E. coli [14,15]. However, there has
been no previous report of an integron carrying
both the aacA4 and aacA7 genes.
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ABSTRACT
Pseudomonas aeruginosa isolates (n = 183), collec-
ted from bacteraemic patients hospitalised in Sa˜o
Paulo Hospital (Brazil) during 2000–2001, were
screened for susceptibility to antimicrobial agents.
The polymyxins were the most active compounds
(100% susceptibility), followed by amikacin and
cefepime (59.0%), meropenem (57.4%), and imi-
penem and gentamicin (55.2%). Imipenem-resist-
ant isolates were ribotyped and screened for
production of metallo-b-lactamases (MBLs) by
PCR with primers for blaIMP, blaVIM and blaSPM.
MBL production was detected in 36 isolates
(19.7% of the entire collection; 43.9% of the
imipenem-resistant isolates) and the MBLs inclu-
ded SPM-1-like (55.6%), VIM-2-like (30.6%) and
IMP-1-like (8.3%) enzymes.
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aeruginosa
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Pseudomonas aeruginosa is a leading cause of
hospital-acquired infections that are often difﬁcult
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